[2]
Traczewski P, Rudnicka L. Adalimumab in dermatology. British journal of clinical pharmacology. 2008 Nov:66(5):618-25. doi: 10.1111/j.1365-2125.2008.03263.x. Epub 2008 Jul 11
[PubMed PMID: 18754844]
[3]
Hinterberger L, Müller CS, Vogt T, Pföhler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatology and therapy. 2012 Dec:2(1):6. doi: 10.1007/s13555-012-0006-6. Epub 2012 May 12
[PubMed PMID: 23205329]
[4]
Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management of Behçet's disease. Therapeutics and clinical risk management. 2015:11():611-9. doi: 10.2147/TCRM.S56163. Epub 2015 Apr 13
[PubMed PMID: 25926738]
[5]
Mettler C, Durel CA, Guilpain P, Bonnotte B, Cohen-Aubart F, Hamidou M, Lega JC, Guern VL, Lifermann F, Poindron V, Pugnet G, Servettaz A, Puéchal X, Guillevin L, Terrier B, French Vasculitis Study Group. Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis. European journal of internal medicine. 2022 Feb:96():97-101. doi: 10.1016/j.ejim.2021.10.028. Epub 2021 Oct 27
[PubMed PMID: 34716074]
[6]
Dai C, Shih S, Ansari A, Kwak Y, Sami N. Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review. American journal of clinical dermatology. 2019 Jun:20(3):409-422. doi: 10.1007/s40257-019-00428-8. Epub
[PubMed PMID: 30895525]
[7]
Vojáčková N, Fialová J, Vaňousová D, Hercogová J. Pemphigus vulgaris treated with adalimumab: case study. Dermatologic therapy. 2012 Jan-Feb:25(1):95-7. doi: 10.1111/j.1529-8019.2012.01433.x. Epub
[PubMed PMID: 22591504]
Level 3 (low-level) evidence
[8]
Kim S, Khatchaturian EM, Dehesa L. Multicentric reticulohistiocytosis: A case report with response to adalimumab. Clinical case reports. 2020 Aug:8(8):1560-1563. doi: 10.1002/ccr3.2926. Epub 2020 Jun 22
[PubMed PMID: 32884795]
Level 3 (low-level) evidence
[9]
Motegi S, Yonemoto Y, Yanagisawa S, Toki S, Uchiyama A, Yamada K, Ishikawa O. Successful Treatment of Multicentric Reticulohistiocytosis with Adalimumab, Prednisolone and Methotrexate. Acta dermato-venereologica. 2016 Jan:96(1):124-5. doi: 10.2340/00015555-2170. Epub
[PubMed PMID: 26072967]
[10]
Kaushik VV. Review of Biosimilars of Adalimumab. The Journal of the Association of Physicians of India. 2017 May:65(5 Suppl):15-21
[PubMed PMID: 28836746]
[11]
Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics : targets & therapy. 2007 Jun:1(2):93-103
[PubMed PMID: 19707319]
[12]
Scheinfeld N. Adalimumab: a review of side effects. Expert opinion on drug safety. 2005 Jul:4(4):637-41
[PubMed PMID: 16011443]
Level 3 (low-level) evidence
[13]
Mease PJ. Adalimumab in the treatment of arthritis. Therapeutics and clinical risk management. 2007 Mar:3(1):133-48
[PubMed PMID: 18360621]
[14]
Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacological research. 2016 Sep:111():592-599. doi: 10.1016/j.phrs.2016.07.015. Epub 2016 Jul 18
[PubMed PMID: 27438459]
[15]
Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2004:18(2):121-39
[PubMed PMID: 15046527]
[16]
Marzan KA. Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions. Adolescent health, medicine and therapeutics. 2012:3():85-93. doi: 10.2147/AHMT.S22607. Epub 2012 Jun 20
[PubMed PMID: 24600289]
[17]
Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clinical and experimental gastroenterology. 2013 Aug 30:6():153-60. doi: 10.2147/CEG.S35163. Epub 2013 Aug 30
[PubMed PMID: 24039442]
Level 3 (low-level) evidence
[18]
Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Therapeutics and clinical risk management. 2008 Apr:4(2):345-51
[PubMed PMID: 18728850]
[19]
Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug design, development and therapy. 2018:12():2005-2016. doi: 10.2147/DDDT.S160431. Epub 2018 Jul 4
[PubMed PMID: 30013320]
Level 1 (high-level) evidence
[20]
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019 Apr:80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13
[PubMed PMID: 30772098]
[21]
Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data. Dermatology reports. 2018 Oct 1:10(2):7859. doi: 10.4081/dr.2018.7859. Epub 2018 Oct 1
[PubMed PMID: 30370041]
[22]
Aby ES, Lake JR, Vaughn BP. The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes. Clinical liver disease. 2020 Nov:16(5):212-217. doi: 10.1002/cld.1005. Epub 2020 Dec 10
[PubMed PMID: 33318791]
[23]
Coşkun BN, Yağız B, Çorabay SG, Pehlivan Y, Dalkılıç E. Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe? European journal of rheumatology. 2022 Apr:9(2):68-74. doi: 10.5152/eurjrheum.2022.21099. Epub
[PubMed PMID: 35546331]
[24]
. ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstetrics and gynecology. 2019 Apr:133(4):e287-e295. doi: 10.1097/AOG.0000000000003176. Epub
[PubMed PMID: 30913201]
Level 3 (low-level) evidence
[25]
Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. International journal of women's health. 2010 Aug 9:2():199-209
[PubMed PMID: 21072312]
[26]
Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Jan:20(1):74-87.e3. doi: 10.1016/j.cgh.2020.09.021. Epub 2020 Sep 12
[PubMed PMID: 32931960]
Level 1 (high-level) evidence
[28]
Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M. Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. Modern rheumatology. 2013 Nov:23(6):1085-93. doi: 10.1007/s10165-012-0796-5. Epub 2012 Dec 5
[PubMed PMID: 23212592]
Level 2 (mid-level) evidence
[29]
Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine. 2017 Aug:96():16-23. doi: 10.1016/j.cyto.2017.02.015. Epub 2017 Mar 6
[PubMed PMID: 28279855]
[30]
Mansitó López C, Torres Laboy P, Ortiz Bou M, Quintero Noriega A, Cintron Rivera V. Fatal New-Onset Congestive Heart Failure Related to Adalimumab Use in a Patient with Relapsing Hidradenitis Suppurativa: A Case Report. The American journal of case reports. 2021 Feb 10:22():e929148. doi: 10.12659/AJCR.929148. Epub 2021 Feb 10
[PubMed PMID: 33563886]
Level 3 (low-level) evidence
[31]
Esposito G, Spennato S, Guerriero L, Ruggiero F, Patrì A, Fabbrocini G, Nastro F. Alopecia areata induced by Adalimumab in a patient with Crohn's disease. Dermatologic therapy. 2022 Dec:35(12):e15940. doi: 10.1111/dth.15940. Epub 2022 Nov 15
[PubMed PMID: 36251322]
[32]
Gorcey L, Gordon Spratt EA, Leger MC. Alopecia universalis successfully treated with adalimumab. JAMA dermatology. 2014 Dec:150(12):1341-4
[PubMed PMID: 25322338]
[33]
Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL Jr, Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis care & research. 2023 Mar:75(3):449-464. doi: 10.1002/acr.25045. Epub 2023 Jan 4
[PubMed PMID: 36597813]
[34]
Ikuta K, Ota Y, Kuroki S, Matsumoto Y, Senda E, Mukohara S, Takahashi S, Monden K, Fukuda A, Seno H, Kumagai S, Shio S. Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment. Internal medicine (Tokyo, Japan). 2020 Mar 15:59(6):849-853. doi: 10.2169/internalmedicine.3295-19. Epub 2019 Nov 22
[PubMed PMID: 31761884]
[35]
Li X, Lau SK, Woo PC. Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. Experimental biology and medicine (Maywood, N.J.). 2020 Jul:245(13):1104-1114. doi: 10.1177/1535370220939862. Epub 2020 Jul 8
[PubMed PMID: 32640893]
[36]
Alzahrani T, Nuqali A, Naser N, Jariwala AR. Adalimumab-induced acute myeloid leukaemia in a patient with Crohn's disease. BMJ case reports. 2019 Feb 3:12(2):. doi: 10.1136/bcr-2018-225680. Epub 2019 Feb 3
[PubMed PMID: 30718264]
Level 3 (low-level) evidence
[37]
Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Alimentary pharmacology & therapeutics. 2020 Mar:51(5):527-533. doi: 10.1111/apt.15637. Epub 2020 Jan 28
[PubMed PMID: 31990422]
Level 1 (high-level) evidence
[38]
Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clinical rheumatology. 2014:33(10):1433-41. doi: 10.1007/s10067-014-2498-1. Epub 2014 Feb 2
[PubMed PMID: 24487484]
[39]
Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. The Journal of clinical and aesthetic dermatology. 2010 Aug:3(8):20-6
[PubMed PMID: 20877538]
[40]
Mulleman D, Balsa A. Adalimumab concentration-based tapering strategy: as good as the recommended dosage. Annals of the rheumatic diseases. 2018 Apr:77(4):473-475. doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6
[PubMed PMID: 29306871]
[42]
Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2017 Feb:76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23
[PubMed PMID: 27338778]
[43]
Kim JS, Geum MJ, Son ES, Yu YM, Cheon JH, Kwon KH. Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis. Gut and liver. 2022 Sep 15:16(5):736-745. doi: 10.5009/gnl210371. Epub 2022 Feb 11
[PubMed PMID: 35145044]
Level 2 (mid-level) evidence